These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17662488)

  • 1. Cerebellar hematoma complicating 600 mg loading dose of clopidogrel in combination with tirofiban.
    Sarkis A; Azar R; Kadri Z; Moussa R; Aoun N
    Int J Cardiol; 2008 Jul; 127(3):e170-1. PubMed ID: 17662488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
    Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
    Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
    Guha S; Sardar P; Guha P; Roy S; Mookerjee S; Chakrabarti P; Deb PK; Chaudhuri U; Deb S; Karmakar R; Dasgupta AK; Lahiri P
    Indian Heart J; 2009; 61(1):68-73. PubMed ID: 19729693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous abdominal hematoma in a patient treated with clopidogrel therapy: a case report.
    Guven A; Sokmen G; Bulbuloglu E; Tuncer C
    Ital Heart J; 2004 Oct; 5(10):774-6. PubMed ID: 15626275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy.
    D'Urbano M; Barlocco F; Poli A; Fetiveau R; Vandoni P; Savonitto S; De Servi S
    J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):737-41. PubMed ID: 18545078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
    Denardo SJ; Davis KE; Tcheng JE
    Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ;
    Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
    Sacristán D; López-Farré AJ; Zamorano-León JJ; Azcona L; Fernández-Ortiz A; Romero J; Farré J; Macaya C
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):286-92. PubMed ID: 18356694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
    Lemesle G; Delhaye C; Sudre A; Broucqsault D; Rosey G; Bauters C; Lablanche JM
    Am Heart J; 2009 Feb; 157(2):375-82. PubMed ID: 19185648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes.
    Wang C; Kereiakes DJ; Bae JP; McCollam P; He J; Griffin B
    J Invasive Cardiol; 2007 Oct; 19(10):431-6. PubMed ID: 17906345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.